Penny Stock Coverage: Is Buying IMMUDYNE INCORPORATED (IMMD) Here Winning Strategy?

November 25, 2016 - By Ruchi Gupta

Penny Stock Coverage: Is Buying IMMUDYNE INCORPORATED (IMMD) Here Winning Strategy?

Interested investors have been looking for information on shares of IMMUDYNE INCORPORATED (OTCMKTS:IMMD) after the stock moved $0.026, hitting the $0.292 price point in a recent trade.

It’s the latest price, but let’s analyze how the stock has been doing recently. In the past year, IMMUDYNE INCORPORATED’s stock was big mover. According to the short interest report published recently, (IMMD) had 4,400 shorted shares for 0 days to cover. The prior short interest was also unknown for a $N/A change. The 52-Week High and Low are noted here. -27.00% (High), 386.67%, (Low). The stock had 366,200 average volume.

Enroll for Our Newsletter Today and know if shares price of IMMUDYNE INCORPORATED (OTCMKTS:IMMD) is Ready to Breakout!

Penny stocks are often stated as risky investments that hardly pay off. Admittedly, there is fact to this, but with the right knowledge and tactics, it is possible to earn a significant amount of gain in penny stocks. Simply said, a penny stock is an equity that trades at a low price.

Irrespective of the name, penny stocks usually are priced over a penny, occupying a price range at or close to $1, though some are priced a fraction of a penny. Often referred to as micro-cap equities, the Securities & Exchange Commission classifies these types of securities as being $5 or less. Over-the-counter stocks are NOT listed on any of the formal exchanges.

So, penny stocks frequently fit in this segment, though many dodge this category. Over-the-counter (OTC) equities are stated to be risky as they aren’t contingent to the listing and reporting requirements of the reputed commodity exchanges.

Register in the Bar Below to Obtain Breaking Alerts on Shares That Are Set to Make a Move!

Penny shares can be listed on NASDAQ or other known stock exchanges, although many more cannot be found there. A major percentage of penny stocks are listed on the so-named ‘pink sheets’, i.e., daily news of OTC shares. They can even be seen on the ‘Over-the-Counter Bulletin Board.’ Commodities listed on the OTCBB fail to fulfill the listing guidelines of the NYSE or other known exchanges, although they are mandated to file financial statements with known regulators, such as the SEC. Penny shares are inexpensive, thus attractive to shareholders who lack the funds to buy comparatively expensive blue-chip stocks from large firms.

Penny stocks boast immense profit potential. Because these stocks trade cheap, even a slight jump in price turns to be profitable. Look out, however, because frequently shareholders may have trouble getting a decent amount of details about penny stocks. These kinds of shares tend to be latest in news, with almost no track record for investors research.

In addition, penny stocks show lack of market activity, with poor liquidity, making them difficult to sell. Poor liquidity results in penny stocks to be open to price influence.

A shady trader can simply buy large sums of shares, temporarily leading up the price, crafting artificial demand.

Disclaimer: Nothing mentioned in this publication is planned to constitute legal, securities, tax, or investment advice, nor a viewpoint regarding the relevance of any investment, nor any type of solicitation. The general information mentioned in this article should not be acted upon without getting specific tax, legal and investment advice from a certified professional.

More notable recent ImmuDyne Inc (OTCMKTS:IMMD) news were published by: which released: “ImmuDyne and Innate Scientific Announce Collaboration and Licensing Agreement …” on October 13, 2015, also with their article: “ImmuDyne Increases its Ownership Interest In Innate Scientific to 78%; Expects …” published on April 08, 2016, published: “ImmuDyne Signs Non-Binding Term Sheet for Exclusive Rights to Dermatologist …” on July 12, 2016. More interesting news about ImmuDyne Inc (OTCMKTS:IMMD) were released by: and their article: “ImmuDyne Signs Exclusive License Agreement for Proprietary Dermatologist …” published on September 09, 2016 as well as‘s news article titled: “ImmuDyne Hires Todd Goldman as Senior Vice President of Marketing and Sales” with publication date: February 10, 2015.

Immudyne, Inc. manufactures, distributes and sells natural immune support products. The company has a market cap of $10.22 million. The Company’s products contain its yeast beta glucans, a group of beta glucans naturally occurring in the cell walls of yeast that have been shown through testing and analysis to support the immune system. It currently has negative earnings. The Company’s products include once a day oral intake tablets and topical creams and gels for skin application.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News